Haemonetics Corporation (HAE) Stock
HAE Key Statistics
About Haemonetics Corporation
Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
CEO: Christopher A. Simon. Company website
HAE — Frequently Asked Questions
What is the HAE stock price today?
Haemonetics Corporation (HAE) trades at $108.42, up 0.76% on the day, as of Sep 20, 2026 14:57 UTC.
What is Haemonetics Corporation's market cap?
Haemonetics Corporation has a market capitalisation of $4.93B, calculated from the live HAE share price and shares outstanding.
What is the P/E ratio of HAE?
HAE trades at a trailing P/E of 53.15, from earnings per share of $2.04 over the last twelve months.
How much revenue does Haemonetics Corporation make?
Haemonetics Corporation generated revenue of $1.35B over the trailing twelve months, which puts the stock at 3.64 times sales.
What is the 52-week range for HAE?
HAE has traded between $47.32 and $110.45 over the past 52 weeks, and the last price is 1.8% below that high.
Is Haemonetics Corporation profitable?
Yes. Haemonetics Corporation keeps 7.12% of revenue as net income over the trailing twelve months.
What is the analyst price target for HAE?
Wall Street analysts rate HAE Buy, with an average price target of $108.60, 0.2% above the current price.
What sector is Haemonetics Corporation in?
Haemonetics Corporation is classified under the Healthcare sector and the Medical - Devices industry, and is domiciled in US.
Who is the CEO of Haemonetics Corporation?
Christopher A. Simon is the chief executive of Haemonetics Corporation, which employs 3,009 people.
Where can I track HAE in real time?
QFI Terminal shows HAE with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See HAE live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open HAE in Terminal See plans